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ABSTRACT
As rapidly developing patient-derived xenografts (PDX) could represent potential 
sources of cancer stem cells (CSC), we selected and characterized non-cultured PDX 
cell suspensions from four different renal carcinomas (RCC). Only the cell suspensions 
from the serial xenografts (PDX-1 and PDX-2) of an undifferentiated RCC (RCC-41) 
adapted to the selective CSC medium. The cell suspension derived from the original 
tumor specimen (RCC-41-P-0) did not adapt to the selective medium and strongly 
expressed CSC-like markers (CD133 and CD105) together with the non-CSC tumor 
marker E-cadherin. In comparison, PDX-1 and PDX-2 cells exhibited evolution in 
their phenotype since PDX-1 cells were CD133high/CD105-/Ecadlow and PDX-2 cells 
were CD133low/CD105-/Ecad-. Both PDX subsets expressed additional stem cell 
markers (CD146/CD29/OCT4/NANOG/Nestin) but still contained non-CSC tumor 
cells. Therefore, using different cell sorting strategies, we characterized 3 different 
putative CSC subsets (RCC-41-PDX-1/CD132+, RCC-41-PDX-2/CD133-/EpCAMlow and 
RCC-41-PDX-2/CD133+/EpCAMbright). In addition, transcriptomic analysis showed that  
RCC-41-PDX-2/CD133− over-expressed the pluripotency gene ERBB4, while RCC-41-
PDX-2/CD133+ over-expressed several tumor suppressor genes. These three CSC 
subsets displayed ALDH activity, formed serial spheroids and developed serial tumors 
in SCID mice, although RCC-41-PDX-1/CD132+ and RCC-41-PDX-2/CD133+ displayed 
less efficiently the above CSC properties. RCC-41-PDX-1/CD132+ tumors showed 
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INTRODUCTION
Current knowledge indicates that the initiation, growth, 
metastasis, chemo-resistance and recurrence of cancers are 
driven by a subset of cells endowed with stem-like properties 
called cancer stem cells (CSCs) or tumor- initiating cells. 
These cells are defined by their capability to self-renew 
and to recapitulate tumor formation when injected in mice 
[1–3]. Therefore, the identification of CSCs and a better 
understanding of their complex characteristics will provide 
very important diagnostic, therapeutic and prognostic targets 
for clinical application [1, 2].
Renal clear cell carcinoma (RCC) is a very 
aggressive cancer resistant to conventional chemo- and 
radiotherapy with an early metastatic evolution [4], and 
it seems likely that renal CSCs may have a relevant role 
in tumor establishment, progression, and recurrence 
[5]. At present, only few reports have investigated the 
presence of CSCs in renal carcinoma. In this context, 
recent histochemistry observations illustrate that the 
human prominin-1 (CD133) antigen, in particular of the 
AC133 epitope frequently employed to isolate CSCs from 
different tumors [6], does not seem a reliable CSC marker 
in RCC [7, 8]. Some groups attempted to identify renal 
CSCs using functional assays such as the ability to form 
spheres in serum-free medium [9] or the presence of the 
so-called Side Population [10]. Following an alternative 
sorting strategy, our group has recently identified, from 
different human RCC specimens a small subset of CSCs 
cells expressing the mesenchymal marker CD105 [11–13]. 
However, further immunohistochemistry studies on 102 
RCC biopsies have shown that CD105 staining could only 
be detected in the cytoplasm of isolated tumor cells in the 
specimens derived from patients with high tumor grade 
and at the highest tumor stage [14]. Finally, it has been 
demonstrated that tumor-initiating cell frequencies were 
remarkably rare in well-differentiated tumors [15–17] 
whereas cancers in which differentiation programs are 
impaired would be comprised of only cells with stem and 
progenitor cell phenotypes [18, 19]. Overall, the above-
mentioned data suggest that the current understanding of 
the renal stem cell system is not complete and that the 
kidney cancer could harbor different CSC pools displaying 
different phenotypes and functions according likely to 
tumor grade, stage and differentiation [14, 19]. Thus, it 
is of major interest to develop new approaches in order to 
identify new putative renal CSCs subsets. 
In these studies, we developed an alternative strategy 
for identifying renal CSCs by adapting to in vitro culture, 
primary cell suspensions from serial Patient-Derived 
Xenografts (PDX). Of note, PDX were obtained by 
serially grafting tumor samples characterized according 
to their different degrees of differentiation, tumor stage, 
and aggressiveness in SCID mice [19]. Cell suspensions 
from PDX of four different RCC patients, characterized 
by the shortest latency for tumor formation in SCID 
mice, were chosen from the Gustave Roussy Institute cell 
collection. The above-mentioned cell suspensions had been 
immediately frozen without in vitro culture (P-0) or after few 
in vitro passages (P-1; P-3), representing therefore invaluable 
material for this type of study [19]. Only the PDX cell 
suspension from one (RCC-41) out of four patients was able 
to adapt to the selective medium growth conditions. RCC-
41 is an undifferentiated RCC, and from its serial xenografts 
(RCC-41-PDX-1 and RCC-41-PDX-2) we isolated, sorted, 
and cloned three novel renal CSCs subsets that diverge from 
each other in phenotypic and functional properties, fulfilling 
however most of the criteria used to identify CSCs. These 
data indicate that even using PDX model, which has been 
reported as a necessary step for the successful isolation of 
renal CSCs from Wilm’s xenograft [20], it is very difficult 
to purify CSCs from RCC. Nevertheless, our data strengthen 
the idea that RCC carcinomas harbor different CSC pools 
displaying different phenotype and functions. In addition, 
the serial PDX derived from a single tumor may help to 
unmask different CSC subsets potentially expressed by a 
single RCC during its in vivo progression, or to generate ex 
novo different CSC-like subsets. 
RESULTS
In vitro selection of RCC cell suspensions derived 
from primary RCC xenografts in SCID mice
To test the hypothesis that patient-derived 
xenografts [18] could represent a source of CSCs in renal 
cell carcinoma, we employed never cultured or first-
passage cell suspensions derived from four primary RCC 
xenografts. These PDXs (RCC-28-PDX-1 and -PDX-2, 
RCC-17-PDX-1 and -PDX-2, RCC-41-PDX-1 and -PDX-2, 
and RCC-47-PDX-1 and -PDX-2) characterized by 
different tumor stage, differentiation, histopathology and 
in vivo aggressiveness [19] (Table 1), were cultured in vitro 
with a selective medium (DMEM-LG) designed to preserve 
CSC stemness properties [12]. Only two cell suspensions 
out of eight (RCC-41-PDX-1 and -PDX-2) adapted to 
the selective medium and could be serially sub-cultured 
(Table 1). Cryopreserved cell suspensions were seeded at 
vessels of human origin with CSC displaying peri-vascular distribution. By contrast, 
RCC-41-PDX-2 originated tumors exhibiting only vessels of mouse origin without CSC 
peri-vascular distribution.
Altogether, our results indicate that PDX murine microenvironment promotes a 
continuous redesign of CSC phenotype, unmasking CSC subsets potentially present 
in a single RCC or generating ex novo different CSC-like subsets.
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5 × 105 cells per 25 cm2 flask. RCC-41-PDX-1 and -PDX-
2 cells adhered to the plastic surface with an efficiency of 
about 40%. After two weeks, RCC-41-PDX-1 and -PDX-2 
cells started to proliferate forming isolated colonies 
exhibiting epithelioid morphology. Upon subculture, 
about 80% of RCC-41-PDX-1 and -PDX-2 cells adhered 
to the plastic surface, started to proliferate, and could 
be serially sub-cultured. Interestingly, the P-0 cell 
suspension derived from the original tumor (RCC-41-P-0) 
adapted to DMEM-LG medium but subsequently could not 
be serially passaged.
Phenotype of RCC-41-P-0 versus RCC-41-PDX-1 
and RCC-41-PDX-2
Flow cytometry analysis of primary RCC-41-P-0 
cells shows that the majority of these cells strongly 
express two CSC stem-like markers: CD133 and CD105, 
while nearly 50% express E-cadherin (Figure 1A). The 
expression of E-cadherin in RCC is a good prognostic 
marker that indicates a tendency towards differentiation 
[21]. CSCs do not express differentiation markers [1–3], 
therefore the expression of E-cadherin suggests the 
persistence of a non-CSC cell fraction [12, 13] in the 
RCC-41-P-0 cell suspension. 
Interestingly, PDX-1 and PDX-2 cell suspensions 
underwent a phenotypic evolution since PDX-1 displays 
a CD133+/CD105–/E-cadlow phenotype and PDX-2 a 
CD133low/CD105–/E-cad– phenotype. These data suggest 
that RCC-41-PDX-1 and -PDX-2 cell suspensions could 
represent a mixture of CSC-like and non-CSC tumor cells. 
We therefore investigated the expression of additional 
CSC and non-CSC markers. Further phenotypic analyses 
(Figure 1B- 1C) show that PDX-1 and PDX-2 share the 
expression of additional CSC markers such as CD29, 
CD146, OCT3/4, Nanog, and Nestin [22–24]. In contrast, 
they diverged in the expression of other markers displaying 
a bimodal distribution such as CD132 (in PDX-1, 
Figure 1C)) and EpCAM (PDX-2, Figure 1B). EpCAM is 
an epithelial surface molecule whose expression in RCC 
is an independent predictor associated with improved 
survival [25], while in several cancers, EpCAM is 
considered as a progression/CSC marker [26]. CD132 
(common gamma chain) is a cytokine receptor sub-unit 
expressed by normal tubular epithelial cells [27, 28] and 
renal CSC-CD105+ [11], whose loss characterizes both 
in vitro and in vivo non-CSC RCC cells [27, 28].
Cell sorting and characterization of RCC-41-
PDX-1 and -PDX-2 subsets 
The above-mentioned results indicate that 
RCC-41-PDX-1 and -PDX-2 express both CSC and 
non-CSC markers. Therefore, we decided to enrich the CSC 
component by cell sorting. In RCC-41-PDX-1 cultures, 
we sorted to eliminate the CD132-negative cells, which 
likely represent the non-CSC fraction [11, 27, 28], and 
selected the CD132-positive cells, which could represent a 
CSC–like subset [11, 24, 27]. In RCC-41-PDX-2 cultures, 
RCC-41-PDX-2/CD133– and RCC-41-PDX-2/CD133+ were 
sorted on the basis of CD133 expression. Subsequently, 
these sorted PDX-1 and PDX-2 subsets were cloned at 
limiting dilution and different clones were derived. 
Flow cytometry analysis shows that sorted 
RCC-41-PDX-1 cells expressed CD132 as a single 
homogeneous peak, associated with low but detectable 
levels of CD133, OCT3/4 and NANOG, and no 
expression of EpCAM (Figure 2A). Sorted RCC-41-
PDX-2/CD133– and RCC-41-PDX-2/CD133+ (Figure 2B) 
shared the expression of equivalent high levels of 
OCT3/4, NANOG but they obviously differed in the 
expression of CD133 and EpCAM. This latter one was 
very faintly expressed in RCC-41-PDX-2/CD133– cells 
and well expressed in RCC-41-PDX-2/CD133+ cells. 
In vitro CSC functional properties of RCC-41-
PDX-1 and -PDX-2 subsets
CSCs are more resistant to conventional chemo-
therapy than differentiated cancer cells. Indeed, CSCs 
employ several mechanisms to protect themselves against 
cytotoxic agents. For example, they have high levels 
of activity of the detoxifying enzymes ALDH, which 
enable them to resist the effects of chemotherapy [29]. 
Therefore, we measured the ALDH activity in RCC-41 
by flow cytometry, using an ALDEFLUOR kit. As 
Table 1: RCC xenografts characteristics
Xenograft Histopathology Stage Grade
Latency 
primaryXenograft 
(days)
Adaptation to 
lowG DMEM
RCC-17-PDX-1 Clear cell granular T4N1M1 3 126 no
RCC-28-PDX-1 Clear cell granular T3N0M0 3 92 no
RCC-41-PDX-1 Undifferentiated
clear cell 
T2N1M1 3 42 yes
RCC-47-PDX-1 Papillary T3NxM0 1 76 no
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shown in figure 3A, sorted RCC-41-PDX-1/CD132+ 
and RCC-41-PDX-2/CD133+ displayed intermediate 
levels of ALDH activity (40 and 60% positive cells 
respectively), while unsorted RCC-41-PDX-2 and sorted 
RCC-41-PDX-2/CD133– displayed high ALDH activity 
(> 80% positive cells) (Figure 3A). We also investigated 
Figure 1: Differential expression of cell surface markers in serially xenografted RCC-41 cells. (A, B, C) The indicated cell 
surface markers were analyzed in primary human cell suspension from RCC-41 tumor sample (RCC-41-P-0) and in cell suspensions from 
RCC-41 patient derived xenograft (RCC-41-PDX-1, RCC-41-PDX-2). Grey histograms correspond to cells incubated with the isotype-
matched control antibody, and black outline histograms correspond to the analyzed markers. Grey numbers within panels correspond to 
Mean Fluorescence Intensity (MFI) of cells incubated with the isotype-matched control antibody, while black numbers correspond to MFI 
of the analyzed markers.
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in the PDX-1 and PDX-2 CSC clones the presence of 
the most primitive cells (Side Population, SP) able to 
extrude the Vybrant violet dye. The experiments were 
performed in the presence or not of the transporter 
inhibitor Verapamil: no SP population could be detected 
in PDX-1 or PDX-2 CSC clones and PDX-1 and PDX-
2 clones did not show significant phenotypic differences 
(data not shown). A remarkable feature of CSCs is their 
capability of self-renewal. Indeed this mechanism is 
required for preservation of the CSC pool [1–3]. In order 
to test their in vitro self-renewal potential, sorted RCC-
41-PDX-1/CD132+ and unsorted RCC-41-PDX-2 cells 
were cultured at concentrations ranging from 102 to 1 cell 
per well in DMEM-LG serum-free medium and assessed 
for spheroid formation (Figure 3B). Within 21 days, 
RCC-41-PDX-1/CD132+  grew forming small spheroids 
with an efficiency of about 40% at the limiting dilution 
of 102 cells per well, while no spheres developed at the 
limiting dilution of 1 cell/well. Unsorted RCC-41-PDX-2 
produced spheroids in about 100% of the wells at 102 cells 
per well, while at the limiting dilution of 1 cell per well, 
RCC-41-PDX-2, sorted RCC-41-PDX-2/CD133– and 
Figure 2: FACS analysis of stem cell and tumor markers in sorted RCC-41-PDX-1/CD132+, RCC-41-PDX-2/CD133+ 
and RCC-41-PDX-2/CD133– cells. (A) Expression level of CD132, CD133, OCT3/4, NANOG, and EpCAM in RCC-41-PDX-1/
CD132+ sorted cells. Results are representative of those obtained in three experiments. (B) Expression level of CD133, OCT-3/4, NANOG, 
and EpCAM in RCC-41-PDX-2/CD133+ and RCC-41-PDX-2/CD133– sorted cells. Results are representative of those obtained in three 
experiments. For (A) and (B), grey histograms correspond to cells incubated with the isotype-matched control antibody, and black outline 
histograms correspond to the analyzed markers. Grey numbers within panels correspond to Mean Fluorescence Intensity (MFI) of cells 
incubated with the isotype-matched control antibody, while black numbers correspond to MFI of the analyzed markers.
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Figure 3: Functional CSC properties in RCC41-PDX-1/CD132+, unsorted RCC-41-PDX2 cells, RCC-41-PDX-2/
CD133–, and RCC41-PDX-2/CD133+ subsets. (A) The aldehyde dehydrogenase (ALDH) activity in sorted RCC-41-PDX-1/CD132+, 
unsorted RCC-41-PDX2, RCC-41-PDX-2/CD133+ and RCC-41-PDX-2/CD133– was measured by flow cytometry (10 000 events). ALDH 
activity was measured in the absence and presence of the specific ALDH inhibitor DEAB following manufacturer’s instructions. One 
experiment representative of three is shown. (B, C) Spheroïd formation following limiting dilution assay of the indicated cells. Data 
represent mean values of five replicates for two experiments; error bars correspond to 95% confidence intervals. (D) Clonogenic activity 
at limiting dilution: sorted RCC-41-PDX-1/CD132+, RCC-41-PDX-2/CD133+ and RCC-41-PDX-2/CD133– were plated in the absence of 
serum at a density of 1 to 10 cells per well in 24-well plates containing DMEM-LG medium. After 2 weeks, each well was examined under 
a light microscope, and the total number of wells with colonies was determined. Data represent mean values of three replicates for three 
experiments; error bars correspond to 95% confidence intervals. 
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RCC-41-PDX-2/CD133+ formed spheroids with respective 
efficiencies of 6, 3, and 1% (Figures 3B and 3C). RCC-
41-PDX-1/CD132+ and -PDX-2 primary spheroids were 
subsequently dissociated using trypsin and were able 
to grow serially as spheroids at their respective limiting 
dilutions. 
Another known CSC property is the capacity to 
form adherent colonies at limiting dilution in serum-free 
medium [2, 3]. Figure 3D shows that RCC-41-PDX-1/
CD132+ and RCC-41-PDX-2/CD133– exhibit high cloning 
efficiency (60% and 40% respectively), while RCC-41-
PDX-2/CD133+ display a lower cloning efficiency (5%). 
Differential expression of the multipotency 
gene ERBB4 and of tumor suppressor genes in 
CD133-negative versus CD133-positive RCC41-
PDX-2 cells
To better understand the growing advantage of 
RCC41-PDX-2/CD133– cells over the RCC41-PDX-2/
CD133+ cells, we performed microarray analysis. 486 
genes were differentially expressed with more than 2-fold 
change and an adjusted p-value of 0.05 (Figure 4A). 
Among them, 63 genes were up-regulated and 423 were 
down-regulated in RCC-41-PDX-2/CD133− versus RCC-
41-PDX-2/CD133+. We first analyzed genes encoding 
cell surface molecules and found that CD133– cells over-
expressed the EGFR family member ERBB4 as compared 
to CD133+ cells, which was confirmed by qPCR (more 
than 20 fold) (Figure 4B). The other family members 
of the ERBB receptors (ERBB1, ERBB2, ERBB3) were 
not differentially expressed, suggesting a selective 
up-regulation of ERBB4 (Figure 4B). Interestingly, 
CD133+ cells displayed by RT-qPCR an increased 
expression for potential tumor suppressor genes such as 
INHBA [30, 31], DIRAS3 [32], S100A14 [33, 34], GPR56 
[35] [35], SPINT2 [36, 37], RNF43 [21, 22, 38–40], 
MT1G [23–25, 41], TAGLN [42] [26, 42], CAV2 [43, 44] 
(Figure 4C). Among these genes, INHBA [30], MT1G [41] 
and SPINT2 [37] were reported to have tumor suppressive 
functions in renal cancers. As well, ANXA3, whose 
decrease was associated with renal cancer development, 
was also augmented [45]. The pro-apoptotic gene CASP4 
[46] was also found to be up-regulated (Figure 4C). 
Tumorigenic potential of human renal RCC-41-
PDX-1/CD132+ in SCID mice
The results depicted in Table 2 shows that 
subcutaneous injection of 103 RCC-41-PDX-1/CD132+-
1.0 cells into SCID mice induced the formation of 
tumors within 3 weeks in all studied mice (n = 8 mice), 
while subcutaneous injection of 102 RCC-41-PDX-1/
CD132+-1.0 induced the formation of tumors in 2 out 
of 8 mice. RCC-41-PDX-1/CD132+-1.0 xenografts were 
enzymatically dissociated and the derived cell suspension 
(RCC-41-PDX-1/CD132+-1.1) was phenotypically 
characterized and subsequently re-injected in SCID mice at 
103 and 102 cells per mouse. RCC-41-PDX-1/CD132+-1.1 
induced the formation of tumors within 3 weeks in 5 
out of 6 mice at both cell concentrations, indicating the 
acquisition of an increased tumor forming efficiency at 
the lower cell concentration. RCC-41-PDX-1/CD132+-1.1 
xenografts subjected to the same enzymatic dissociation 
procedure produced the derived cell suspension termed 
RCC-41-PDX-1/CD132+-1.2. These cells exhibited a 
highly decreased capacity to form tumors in the SCID 
mice: after 3 weeks only 1 out of 6 mice developed a 
tumor and only at the concentration of 103 cells. These 
data show that in SCID mice, RCC-41-PDX-1/CD132+ 
generates serially transplantable tumors with a variable 
efficiency. The important differences in the tumor-forming 
ability observed in the serial RCC-41-PDX-1/CD132+ 
xenografts led us to investigate whether these variations 
could be associated with a modified expression of CSC 
markers. For this purpose, we analyzed the phenotypes 
of all injected cell suspensions. Flow cytometry analysis 
indicates that the percentage of CD133+ cells present in 
the cell suspension injected in the SCID mice directly 
correlated to the tumor forming ability of the cells 
(Figure 5A) suggesting therefore that, contrary to what 
previously reported [7, 8], CD133 may help to identify 
subsets of CSCs in RCC.
Progressive epithelial differentiation and 
presence of human vessels in RCC-41-PDX-1 
serial tumors
Histologic analysis of tumors serially generated in 
SCID mice (RCC-41-PDX-1/CD132+-1.0, –1.1 and –1.2) 
shows a homogenous histopathology consisting of highly 
mitotic undifferentiated carcinomas, and rare clear cells 
(Figure 5B). Co-staining with anti-hCD31 and anti-
hCD133 antibodies shows that several vessels of human 
origin are detectable in the serial xenografts (Figure 5B) 
and that CD133+ cells display a peri-vascular distribution 
(Figure 5B) that is maintained in the serial xenografts 
even if their frequency progressively decreases. In 
serial xenografts starting from PDX-1.1, we observed 
the appearance of cells expressing the human epithelial 
marker EpCAM (Figure 5B), which strongly increases 
in PDX-1.2, suggesting a natural tendency towards 
epithelial differentiation, that is associated with a rarefied 
frequency of CD133+ cells (Figures 5A and 5B). Thus, 
RCC-41-PDX-1/CD132+ cells are able to generate 
serially transplantable tumors in SCID mice, which 
recapitulate the histopathology of the original RCC and 
show a tendency for a progressive engagement in an 
epithelial differentiation pathway. This was confirmed by 
the increased expression of E-cadherin and the decreased 
expression of vimentin analyzed by RT-qPCR (Figure 5C). 
Interestingly, flow cytometry analysis performed on 
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Figure 4: mRNA expression profiles of RCC41-PDX-2/CD133– and RCC41-PDX-2/CD133+ subsets. (A) Microarray 
analysis of CD133+ and CD133– RCC41-PDX-2 cells. Two independent biological replicates are represented. (B, C) Comparative mRNA 
expression of ERBB receptors (B) and tumor suppressor genes (C) in CD133– and CD133+ RCC41-PDX-2 cells by RT-qPCR. Presented 
results are mean of three independent experiments with *p < 0.05, **p < 0.005, and ***p < 0.0005.  
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RCC-41-PDX-1/CD132+-1.1 tumor cell suspensions 
reveals the presence of three subsets: a first subset of 
CD133–/EpCAM+ (17%) represents a fraction of non-CSC/
RCCs, while two smaller subsets of CD133+/EpCAM– 
(4%) and CD133+/EpCAM+ (10%) cells (Figure 5D) likely 
represent RCC-41 CSCs differing for the acquisition of 
EpCAM [26].
Tumorigenic potential of human renal unsorted 
RCC-41-PDX-2 and RCC-41-PDX-2 subsets in 
SCID Mice
Subcutaneous injection of 103 and 102 RCC-41-
PDX-2 and RCC-41-PDX-2/CD133– cells into SCID mice 
generated tumors within 3 weeks (n = 4) (Table 3 and 
Figures 6A and 6B). RCC-41-PDX-2-generated tumors 
grew twice as fast as RCC-41-PDX-2/CD133– tumors in 
a statistically significant way (Figures 6A and 6B). Indeed, 
RCC41-PDX-2-injected mice developed large tumors (1500 
mm3) within 4 weeks of injection whereas mice engrafted 
with RCC41-PDX-2/CD133– cells reached this volume 
after 8 weeks (Figures 6A and 6B). By contrast, RCC-
41-PDX-2/CD133+ subset exhibited a consistent reduced 
tumor forming efficiency as compared to RCC41-PDX-2 
and RCC-41-PDX-2/CD133–. Indeed, RCC-41-PDX-2/
CD133+ formed smaller palpable tumors (100 mm3) 
detected in the injected mice after 9 weeks and only at 
the concentration of 103 cells per mouse (Figure 6). This 
differential tumor growth was statistically significant, and 
indicated that the RCC41-PDX-2/CD133– subset displays 
a higher tumorigenic potential than the CD133+ subset.
Loss of human endothelial micro-vessels (EM) in 
RCC-41-PDX-2 tumors
H&E staining of tumors generated in SCID mice 
by RCC-41-PDX-2, and RCC-41-PDX-2/CD133–, RCC-
41-PDX-2/CD133+ and their respective clones, shows 
that PDX-2 xenografts exhibit histopathology similar 
to that observed in PDX-1 tumors, consisting of highly 
mitotic undifferentiated carcinomas, and rare clear cells 
(Figure 7A). Immunofluorescence analysis of tumor vessels 
shows off a remarkable property that distinguishes RCC-
41-PDX-1/CD132+ from RCC-41-PDX-2 xenografts: in 
all PDX-2 xenografts, vessels are entirely of murine origin 
as shown by EM counts using hCD31 and mCD34 mAbs 
proved to be rigorously species-specific in a previous study 
[47]. All vessels present in PDX-2 xenografts were lined 
with mCD34+ endothelial cells, whereas vessels lined with 
hCD31+ endothelial cells were never detected (Figure 7A). 
Moreover PDX-2/CSCs, identified in vivo through the 
expression of CD146, were detected nearby murine vessels 
but did not show the strict peri-vascular distribution 
detected in PDX-1 xenografts (Figure 7B). 
DISCUSSION
The identification of renal CSCs represents a 
therapeutic priority that, for the moment, remains somewhat 
elusive due to RCC genetic and histological heterogeneity 
[4, 5]. Recently, a CSC population expressing CD105 was 
purified from RCC patients [12]. An immunohistochemical 
study, performed on paraffin-embedded tumor samples 
derived from 102 RCC patients, showed that CD105 
expression in tumor cells was found in high-grade tumors 
and highest tumor stages [14]. This would suggest that RCC 
may harbor CSCs with different phenotypes [5]. Thus we 
developed an alternative strategy for identifying putative 
renal CSCs, different from the CD105+ cell sorting [12]. 
For this purpose, we exploited the Gustave Roussy Institute 
cell bank; using never-cultured cell suspensions derived 
from the four more aggressive serial RCC-PDX displaying 
different phenotypes, tumor stage and grade [19, 48]. Only 
RCC-41-PDX-1 and -PDX-2 cell suspensions out of four 
different RCC-PDX adapted to the selective medium 
conceived for preserving in vitro the stem cell properties 
[12]. Interestingly, we also tried to culture the primary cell 
suspension derived from the original tumor (RCC-41-P-0); 
however, while the cells attached and grew slowly up to 
near confluence, they could not be further passaged. 
Comparison of the phenotype of RCC41-P-0, RCC-
41-PDX-1 and RCC-41-PDX-2 primary cultures showed 
major phenotypic differences. Indeed, RCC-41-P-0 cells 
expressed a CD133bright/ CD105brigh/E-Cadherin+ phenotype. 
Table 2: Serial tumor formation of RCC-41-PDX-1/CD132+ cells in SCID mice as a function of 
number of injected cells
Number of injected cells per mouse 
(n = 6 to 8)
Number of mice with tumors
(Delay 3 weeks)
RCC-41-PDX-1/CD132+-1.0
102 2/8
103 8/8
RCC-41-PDX-1/CD132+-1.1
102 5/6
103 5/6
RCC-41-PDX-1/CD132+-1.2
102 0/6
103 1/6
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Figure 5: Tumorigenic potential of human renal RCC-41-PDX-1/CD132+
 
in SCID mice. (A) Flow cytometry analysis of 
CD133 expression in RCC-41-PDX-1/CD132+ cell suspensions recovered from serial xenografts in SCID mice. Red outline histograms 
correspond to analyzed markers, and blue outline histograms correspond to cells incubated with the isotype-matched control antibody. 
(B) Vessel staining (CD31) and serial tumor formation by RCC-41-PDX-1/CD132+ cells subcutaneously injected in SCID mice. Top row: 
Representative hematoxylin and eosin staining showing the morphological appearance of an undifferentiated renal carcinoma with rare 
clear cells. Middle row: Representative immunohistochemistry of serial tumor sections showing positivity for human CD31 using a mAb 
that did not cross-react with the mouse CD31 (tumor vessels) and human CD133. CD133+ cells show a typical peri-vascular distribution. 
Bottom row: Representative immunohistochemistry of serial tumor sections showing positivity for human EpCAM. Original view × 40 (top) 
and × 60 (middle and bottom). Data are representative of 3 experiments with similar results. (C) Quantative PCR analysis of E-cadherin 
(CDH1) and Vimentin (VIM), expression in RCC-41-PDX-1/CD132+ cells. Data were normalized using TATA binding gene mRNA (TBP), 
as endogenous control. (D) Flow cytometry analysis of CD133 and EpCAM expression in RCC-41/PDX-1/CD132+-1.1 cell suspension 
recovered from serial xenografts in SCID mice. 
Oncotarget11www.impactjournals.com/oncotarget
The unusual high expression of the stemness markers 
CD133 and CD105 is probably related to the fact that 
RCC-41 is an undifferentiated tumor [48] and points out 
the likely existence in RCC-41-P-0 of a large proportion 
of very primitive CSC-like cells, while the expression of 
E-cadherin supports the presence of  differentiated non-
CSC tumor cells [21, 49, 50]. By contrast, RCC-41-PDX-1 
expressed a CD105–/ CD133+/E-cadherinlow phenotype 
while RCC-41-PDX-2 were CD105–/CD133low/E-cad–. 
In order to further enrich RCC-41-PDX-1 and RCC-41-
PDX-2 subsets in CSC, we developed different cell sorting 
strategies. Sorted cells were cultured and amplified over 
two in vitro passages, analyzed for their phenotype, and 
subsequently cloned at limiting dilution. Using the PDX 
model, we selected three potential CSCs subsets that could 
be further distinguished on the basis of the expression of 
the CSC-like marker EpCAM [26]: CSC/PDX-1/CD132+/
EpCAM–, CSC/PDX-2/CD133–/EpCAMlow, and CSC/PDX-
2/CD133+/EpCAMbright. 
The sorted CSC/PDX-1 and CSC/PDX-2 subsets, 
as well as their respective clones, display properties 
typical of CSCs detected in other solid tumors. Namely 
they: 1) express stem cell markers, 2) exhibit clonal 
growth at limiting dilution, 3) grow and can be serially 
transferred as floating spheroids, 4) express mid-high 
levels of the detoxifying enzyme ALDH, a typical CSC 
marker [51], and 5) generate serially transplantable 
tumors characterized by similar histopathology. However 
it must be stated that serial PDX-1/CD132+ xenografts 
displayed microvessels of human origin and strict 
peri-vascular distribution of CSCs that favors the 
preservation of stemness [52], while PDX-2 xenografts 
exhibited microvessels of murine origin without peri-
vascular distribution of CSCs. 
In addition, between PDX-1/CD132+-1.1 and 
PDX-1/CD132+-1.2 xenografts, we observed a decreased 
frequency of CD133+ CSCs while an increasing fraction 
of tumor cells expressed EpCAM. More precisely, 
double staining performed on PDX-1/CD132+-1.1 cell 
suspensions indicates the presence of three different 
subpopulations: i) PDX-1/CD132+/CD133–/EpCAM+ 
cells, ii) PDX-1/CD132+/CD133+/ EpCAM– cells and 
iii) PDX-1/CD132+/CD133+/ EpCAM+ cells. Thus, we 
propose that serial xenografts of PDX-1/CD132+ in 
SCID mice progressively produce differentiated tumors, 
as shown by the increased expression of E-cadherin, 
the absence of vimentin expression, and the massive 
appearance of CD133–/EPCAM+ cells, that in PDX-1/
CD132+-1.2 xenografts constituted more than 70% of 
the non-CSC tumor cell bulk. On the other hand, the 
PDX-1/CD132+/CD133+/EpCAM– cells represent the 
original CSC/PDX-1/CD132+ subset, while the PDX-1/
CD132+/CD133+/EpCAM+ cells probably represent a new 
emerging majoritary CSC subset.
Finally, in PDX-2 xenografts, murine microen-
vironment induces a remodeling of the CSC properties 
favoring the appearance of two novel subsets of less 
primitive CSC since they have lost the potential to 
generate human microvessels and are characterized by 
different phenotypes: PDX-2/CD133–/EpCAM–/ERBB4+ 
is the predominant aggressive subset while the PDX-2/
CD133+/EpCAMbright is a minor, less aggressive CSC 
subset characterized by the expression of several tumor 
suppressor genes.
In conclusion, our data support the idea that the 
serial PDX derived from a single tumor may help to 
unmask the different CSC subsets potentially expressed by 
a single RCC during its in vivo progression. Alternatively, 
it is also possible to postulate that the PDX CSC niche, 
which is of murine origin, could redesign the properties of 
human CSC favoring the generation of modified CSCs that 
become unable to generate human microvessels hampering 
somehow the development of targeted anti-angiogenic 
preclinical approaches.
Table 3: Tumor formation of unsorted RCC-41-PDX-2, and sorted RCC-41-PDX-2/CD133+ and 
RCC-41-PDX-2/CD133− cells in SCID mice as a function of number of injected cells  
(n = 4 per group)
Number of 
injected
cells per mouse 
(n = 4)
Number of mice 
with tumor
(Delay 3 weeks)
Number of mice 
with tumor
(Delay 6 weeks)
Number of mice 
with tumor
(Delay 9 weeks)
Number of mice 
with tumor
(Delay 10 weeks)
Unsorted RCC-41-
PDX-2
102 3/4 4/4 - -
103 4/4 4/4 - -
RCC-41-PDX-2
/CD133+ 
102 0/4 0/4 0/4 0/4
103 0/4 0/4 4/4 4/4
RCC-41-PDX-2
/CD133– 
102 2/4 2/4 2/4 4/4
103 3/4 4/4 4/4 4/4
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Figure 6: Tumorigenic potential of human renal RCC-41-PDX-2 and RCC-41-PDX-2 subsets in SCID mice. (A) Tumor 
formation of unsorted RCC-41-PDX-2, and freshly sorted RCC-41-PDX-2/CD133– and RCC-41-PDX-2/CD133+ cells in SCID mice as a 
function of number of injected cells 102 and 103 cells of each cell subtype were subcutaneously injected into SCID mice (n = 4 per group). 
Represented is the time for evaluation of tumor volume (mm3). Data are representative of 3 independent experiments with similar results. 
(B) Representation of tumor growth rate using survival curve. Death corresponds to a xenografted tumor reaching 1500 mm3. Data are 
representative of 3 independent experiments with similar results. *and **in (C) indicates respectively p < 0.05 and p < 0.005 by the log-
rank test.
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Figure 7: Vessel staining in human renal unsorted RCC-41-PDX-2 and RCC-41-PDX-2 cell subsets subcutaneously 
injected in SCID mice. (A) Representative hematoxylin/eosin and immunofluorescence stainings of serial tumor sections showing 
positivity for mouse CD34 but not for human CD31 antibodies in RCC-41/PDX-2-derived
 
xenografts. (B) Representative immunofluo-
rescence stainings of serial tumor sections showing positivity for mouse CD34 and human CD146 antibodies in RCC-41/PDX-2 subsets.
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MATERIALS AND METHODS
Cell culture
Cell suspensions from 4 different RCC-PDX 
xenografts (RCC-17-PDX-1 and -PDX-2, RCC-28-PDX-1 
and -PDX-2, RCC-41-PDX-1 and -PDX-2, RCC-47-PDX-1 
and -PDX-2) that resulted in tumor development in SCID 
mice [19] and RCC-41-P-0 were adapted to in vitro culture 
using a multipotent adult progenitor cell medium consisting 
of DMEM-LG (Invitrogen, Paisly, UK) with insulin-
transferrin selenium 1x (Invitrogen, Paisley, UK), 10–9 M 
dexamethasone, 100 U penicillin, 1000 U streptomycin, 
10 ng/ml epidermal growth factor (EGF) (Sigma-Aldrich) 
and 5% FCS (Euro Clone, Wetherby, UK). Adherent cells 
were maintained in complete DMEM-LG for more than 
30 passages, with no change in the expression of stem cell 
markers as determined by FACS analysis. 
Antibodies, cytokines, and reagents
Conjugated antibodies against NANOG (phyco-
erythrin (PE) conjugated goat polyclonal (IC1997P), 
1:200 dilution), OCT-3/4 (PE conjugated goat polyclonal 
(IC1759P), 1:200 dilution), and Nestin (PE conjugated 
mouse monoclonal (IC1259P), 1:200 dilution) were 
purchased from R&D Systems Europe Ltd (Abingdon, 
UK). Fluorescein isothiocyanate (FITC)-conjugated anti-
CD90 (mouse monoclonal, 1:100 dilution) was purchased 
from Dianova GmbH (Hamburg, Germany). 
All other antibodies used for cytofluorimetric 
analyses (FACS) were directly conjugated with FITC, PE, 
or APC: anti-CD31, antiCD-146/Muc-18, anti- CD29, 
anti-CD105, and anti-CD133 monoclonal antibodies 
(mAbs) (all from Miltenyi Biotec, Cologne, Germany); 
mAb anti-EpCAM (Biolegend, San Diego, CA). Isotype-
matched FITC-, PE-, or APC- conjugated control mouse 
G (IgG) were from Miltenyi. 
Sphere formation assay
We evaluated the self-renewal capacity of RCC-
41-PDX-1/CD132+, RCC-41-PDX-2, RCC-41-PDX-2/
CD133+, and RCC-41-PDX-2/CD133– by performing 
a limiting dilution assay for spheroid formation. Cells 
were plated using a FACS DiVa cell sorter equipped with 
autoclone software (Beckton Dickinson, Le Pont-de-Claix, 
France) at a density of one and 100 cells per well 
in ultralow attachment 96-well plates (Corning Life 
Sciences, Acton, MA). Each well was supplemented with 
200 μl of serum-free complete DMEM-LG. After 3 weeks, 
each well was examined under a light microscope and the 
total number of wells containing spheroid colonies was 
determined. Five replicates were used for each condition, 
and the experiment was repeated two times. 
RNA extraction and quantitative real time 
reverse transcriptase polymerase chain 
reaction
Total RNA was isolated from cells using TRIZOL 
reagent (Invitrogen), according to manufacturer’s 
instructions. RNA was quantified spectrophotometrically 
(Nanodrop ND-1000, Wilmington DE). Primers used for 
qRT-PCR are shown in Table 4; other primer sequences 
are available upon request.
To detect mRNA expression, first-strand cDNA was 
produced from 200 ng of total RNA using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA). Real-time PCR experiments were 
performed in 20 µl reaction mixture containing 5 ng of 
cDNA template, the sequence-specific oligonucleotide 
primers (purchased from MWG-Biotech AG, Ebersberg, 
Germany, www.mwg-biotech.com) and the Power SYBR 
Green PCR Master Mix (Applied Biosystems). Negative 
cDNA controls (no cDNA) were cycled in parallel with each 
run. qRT-PCR was performed using a 96-well StepOneTM 
Real Time System (Applied Biosystems). mRNA 
comparison between samples was calculated on relative 
expression data normalized using TATA binding protein 
(TBP), as endogenous control. Fold change expression with 
respect to controls was calculated for all samples.
Flow cytometry
For all assays described below, we acquired 
fluorescence data for 10,000 events on a FACSCalibur 
flow cytometer (BD Biosciences, Oxford, UK) and 
analyzed the data with the use of CellQuest software (BD 
Biosciences) or FlowJo (Treestar). The experiments were 
repeated at least three times. In some experiments, cells 
were analyzed on a FACScan (Becton Dickinson, Franklin 
Lakes, NJ, USA). 
Expression of cellular antigens
Expression of cell surface (E-cadherin, CD105, 
CD133, EpCAM, CD132 (IL-15Rγ), CD29, CD146) 
and intracellular (OCT-3/4, NANOG, Nestin) proteins 
was analyzed by flow cytometry as previously described 
[11, 12]. Briefly, suspensions of enzymatically- 
or EDTA-detached cells were permeabilized (for 
intracytoplasmic staining) or not (for cell surface 
staining) with BD Cytofix/Cytoperm 5 reagent (BD 
Pharmingen, Le Pont-De-Claix, France). 5 × 105 cells 
were suspended in DMEM-LG medium supplemented 
with 1% FCS and stained with conjugated antibodies 
directed against the above-mentioned cell markers at the 
dilutions indicated in the “Antibodies, Cytokines, and 
Reagents” section. Cells were subsequently analyzed by 
flow cytometry. 
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ALDH detection
ALDH activity was assessed by flow cytometry 
in RCC-41-PDX-1/CD132+ and -PDX-2 subsets using 
ALDEFLUOR kit (StemCell Technologies, Grenoble, 
France) in accordance with the manufacturer’s 
instructions. Briefly, 106 cells from RCC-41-PDX-1/
CD132+ and -PDX-2 subsets were incubated with BODIPY 
aminoacetaldehyde, which is converted into a fluorescent 
molecule (BODIPY aminoacetate) in the cytoplasm. 
Specificity of the fluorescence was shown using the 
specific ALDH inhibitor diethylaminobenzaldehyde 
(DEAB). 
Tumorigenic potential of RCC-41-PDX-1/
CD132+ and -PDX-2 cells in severe combined 
immunodeficient (SCID) mice
RCC-41-PDX-1/CD132+ and -PDX-2 subsets were 
harvested by incubation with trypsin–EDTA, washed 
in PBS and resuspended in 100 μL of DMEM. Aliquots 
of 102 or 103 cells were added to 100 μL of Matrigel 
(BD Biosciences), chilled on ice, and injected 
subcutaneously with a 1-mL syringe fitted with a 26-gauge 
needle into the left and right sides of 6-week-old male 
SCID mice (Charles River, Jackson Laboratories, Bar 
Harbor, ME). Four to eight mice were injected with each 
of the different RCC-41 subsets. We performed three 
independent experiments. At different times after cell 
injections (3, 6, 9, and 10 weeks) the mice were killed by 
carbon dioxide asphyxiation and their tumors were excised, 
weighed, and measured. Studies were approved by the 
Italian Ministry of Health and by the Institutional Review 
Board of the University of Turin and were performed in 
accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals (Institute of 
Laboratory Animal Resources: 7th ed. Washington, DC, 
Institute of Laboratory Animal Resources, Commission on 
Life Sciences, National Research Council, 1996). 
Immunofluorescence
Indirect immunofluorescence was performed 
on formalin-fixed, paraffin-embedded tissue sections 
from 5 xenograft tumors as previously described [47]. 
Paraffin sections (4 μm thick) were processed by 
standard deparaffinization with xylene and hydrated in 
a descending ethanol series to double-distilled water. 
Antigen retrieval on formalin-fixed tissue section was 
performed using Sodium-Citrate buffer (pH 6.0). Indirect 
immunofluorescence was performed using the following 
primary antibodies: anti-human (h) CD31, monoclonal 
mouse (diluted 1/100; Dako Cytomation, Hamburg, 
Germany) and anti-mouse (m) CD34, monoclonal 
rat (diluted 1:100; Novus Biologicals, Littleton, CO, 
USA), anti-CD133 (h) (Miltenyi), and anti-EPCAM 
(h) (Biolegend). Slides were incubated with primary 
antibodies overnight at 4°C. Secondary antibodies used 
were: goat anti-mouse IgG Alexa-568 and goat anti-rat 
IgG Alexa-568 (diluted 1:200; Invitrogen, Germany). 
After washing, the slides were counterstained with 
4′,6′-diamidino-2- phenylindole (DAPI, Sigma-Aldrich, 
Milan, Italy) and cover-slipped.
The endothelial micro-vessels (EM) were assessed 
by anti-hCD31 and anti-mCD34 staining and examination 
of twenty microscopic fields (0.5 mm2) per tumor. The 
most intense vascular areas (hotspots) were selected 
subjectively from each tumor section. The micro-vessels 
with a clearly defined lumen or well-defined linear vessel 
shape were taken into account.
For image analysis, digital images were collected 
using a Nikon E-1000 fluorescence microscope (Nikon 
Instruments, Tokyo, Japan) equipped with appropriate 
filter sets and the Genikon imaging system software 
(Nikon Instruments).
Statistical analysis
For tumor studies in mice, the number of animals per 
group was based on our acquired expertise after 4 years of 
experiments with this model (we did not perform power 
calculations to determine the number of mice per group). 
The unit of analysis was the mouse, and the average of all 
tumors per mouse was taken into account. For the survival 
curves, the log rank test was used to compare the survival 
of the different groups. Otherwise, the two-sided Student’s 
t test was used to compare groups. A P value less than .05 
was considered statistically significant. 
Table 4: Primer sequences
Gene Symbol/gene ID: Primer sequence
E-CADHERIN CDH1 / 999 FWD: 5′-GCATTGCCACATACACTCTCTTCT-3′
REV: 5′-GCTTGTTGTCATTCTGATCGGTTA-3′
VIMENTIN VIM / 7431 FWD: 5′-GGAACAGCATGTCCAAATCGAT-3′
REV: 5′-CAGCAAACTTGGATTTGTACCATT-3′
TATA BINDING 
PROTEIN
TBP / 6908 FWD: 5′-TGTGCACAGGAGCCAAGAGT3-3′
REV: 5′-ATTTTCTTGCTGCCAGTCTGG-3′
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